INTRODUCTION

SLEEP IS A NORMAL CONDITION OF THE BODY WHICH OCCURS PERIODICALLY AND IS ASSOCIATED WITH A DEPRESSION OF PHYSIOLOGICAL FUNCTION.
In general, since humans do not take any nutritional materials for a few hours before sleep, the sleep must be induced by a trace amount of endogenous substances. According to the receptor theory, the sleep could be easily understood to occur by interaction between induced substance and certain receptors. This review focuses on our recent works involving the studies of hypnotic activities of N 3 -substituted uridine and the uridine receptor.
Despite the extensive efforts for elucidation of sleep phenomenon, we know very little about the occurrence, control, and regulation mechanism of the sleep. Many theories on sleep mechanism have been described as follows; (1 toxic substance, 1 (2 body fluid, (3 diminishing of energy and (4 biologic amine. 2 Many endogenous substances are known to cause sleep-prompting effects. 3 These substances are called endogenous sleep factors (sleep-promoting substances, SPS). Prostaglandin D2 and cis-9,10-octadecenoamide have been identified as a natural constituent in brains of mammals that induces natural sleep. 4, 5 Delta sleep inducing peptide (DSIP) was originally found in venous blood of sleeping rabbits and was identified as a nonapeptide and also promotes sleep. 6, 7 Oxidative glutathione was purified from sleep-deprived brainstems of rats. 8 Other endogenous substances were isolated from cerebral fluid of sleep-deprived goats 9 and human urine. 10 These studies suggest that endogenous substances may play a role in sleep. In 1983, Komoda et al. 11 reportAbstract: This review deals with the concept of sleep mechanism based on our uridine receptor theory. It is well established that uridine is one of the sleep-promoting substances, we have, therefore, synthesized new types of hypnotic compounds from oxopyrimidine nucleosides. Their mechanism of action in CNS depressant effects is elucidated based on the receptor theory. In this study, structure-activity relationship for CNS depressant properties, sleep-promoting effects, interaction with certain CNS receptors, and receptor binding assay of uridine derivatives as oxopyrimidine nucleoside were investigated.
In the studies of structure-activity relationship of N 3 -substituted uridine, we found for the first time that both N 3 -benzyluridine and N 3 -phenacyluridine synthesized exhibited potent hypnotic activity (loss of righting reflex) by intracerebroventicular injection in mice. Moreover, certain derivatives of these compounds possessed synergistic effects with barbiturate and benzodiazepine, and decreased in spontaneous activity, motor incoordination, and antianxiety effects in mice. Especially, N 3 -phenacyluridine markedly enhanced pentobarbital-and diazepam-induced sleep by 6-and 70-fold, respectively. However, N 3 -benzyluracil and N 3 -phenacyluracil that have no ribose moiety did not possess any hypnotic activity, indicating specific effects of nucleoside derivatives. Effects of N 3 -benzyluridine on natural sleep in rats were thus examined. N 3 -Benzyluridine also possessed the sleep promoting effect assessed by electrocorticogram at the dose of 10 pmol. For elucidating the mechanism of action of N 3 -phenacyluridine, the interactions of this compound with benzodiazepine, GABA, 5-HT, or adenosine receptors were also investigated. Although the pharmacological activity of N 3 -phenacyluridine was high, the affinities to benzodiazepine, GABA, 5-HT, and adenosine receptors were quite low.
[ 3 H]N 3 -Phenacyluridine concentration-dependently bound to synaptic membrane prepared from the bovine brain. The Scatchard analysis revealed a single component of the binding site. This binding site is proposed here as a novel receptor called "uridine receptor" for hypnotic activity of the uridine derivatives. The rank order of the distribution of these specific binding sites was found to be striatum > thalamus > cerebral cortex > cerebellum > mid brain > medulla oblongata in the rat brain. In the metabolic study of N 3 -phenacyluridine, we found that this compound was exclusively metabolized to N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine, but not the (R)-form, in mice. N 3 -(S)-(+)-α-Hydroxy-β-phenylethyluridine possessed not only strong hypnotic activity but also a high affinity to the uridine receptor of synaptic membranes, while the (R)-isomer was low in both activities. Racemic mixture was shown to be intermediate for pharmacological effects of the compounds. These studies which used (R)-or (S)-isomer indicate that uridine binding site or uridine receptor, exists in the CNS and plays some role in sleep regulation in mammals as one of the triggering steps in inducing hypnotic activity.
It is suggested that uridine is released from steps of nucleic acidnucleic protein biosynthesis (catabolism), and reaches the binding sites in the areas of the brain which regulate natural sleep. The uridine dissociated from the receptor is then utilized for the synthesis of nucleic acid (anabolism). We propose here that the induction of sleep may be mediated by uridine through uridine receptor in the CNS, although the structure of uridine receptor is not yet elucidated. Key words: Sleep mechanism; uridine; N 3 -Phenacyluridine; N 3 -benzyluridine; N 3 -(S)-(+)-α-Hydroxy-β-phenylethyluridine; hypnotic; CNS depressant effects; uridine receptor; receptor binding.
ed that uridine was one of the endogenous sleep-promoting substances isolated from brainstems of 24-hour sleep-deprived rats. The nocturnal infusion of small amounts of uridine (10 pmol) caused the enhancement of natural sleep in rats determined by electroencepharogram. 7 Uridine is a nucleic acid which is widely involved in a variety of biochemical processes and is ubiquitously distributed in the organism and tissue, including the brain. The nucleic acid that serves as the precursor of RNA and UDP-glucose, plays a role in multiplying cells, etc. As shown in Figure 1 , uridine consists of uracil as base moiety and D-ribose as sugar moiety on its structure. It is also known that the compound has the same oxopyrimidine ring in the structure as that of barbiturates, nonbarbiturate anesthetics, and antiepileptics. It is further noted that the basic structure of the barbiturates is similar to that of uracil. Fontenot et al. 12 showed that administration of pentobarbital having oxopyrimidine ring resulted in increase in nucleoside incorporation into RNAs and DNAs in mice. The finding suggests the closed relationship between anabolism or catabolism of nucleosides and action of barbiturates. Although many investigators reported pharmacological properties of barbiturates including development of tolerance and physical dependence, the mechanism for hypnotic action of barbiturates is still unclear. [13] [14] [15] Methaqualone (2-methyl-3-o-tolyl-4-(3H)-quinazolinone), a nonbarbiturate with N-tolyl group, was used as a hypnotic drug in 1960~1970 in Japan; its structure includes the uracil base moiety. (Figure 2 ) 16 Other N-substituted CNS depressants are also evident in methylhexabital, hexobarbital, chlordiazepoxide, and flunitrazepam. There is no evidence to show that N 3 -substituted oxopyrimidine nucleosides possess sedative and hypnotic activities. For these reasons described above, we performed the studies of structure-activity relationship of uridine, one of the oxopyrimidine nucleoside derivatives that exhibits CNS depressant activity. It is hoped that the sleep mechanism may be elucidated by searching for the action mechanism of these compounds.
Structure-Activity Relationship of Uridine Derivatives in Sedative and Hypnotic Activities
It is known that uridine consists of oxopyrimidine as base ring and ribose. The CNS depressant effects of uracil and its derivatives, such as anticonvulsant effects 17 and synergism with barbiturates, 18 were reported. In addition, uridine also had anticonvulsant activity other than the sleep-promoting effect. 19 These lines of evidence suggested the participation of nucleic acid and/or nucleoside in the CNS depression, including sedative and hypnotic activities.
In the studies of the structure-activity relationship of oxopyrimidine nucleoside derivatives in sedative and hypnotic activities, we attempted to synthesize various oxopyrimidine nucleoside derivatives and investigated their CNS depressant effects. Since then, we have found for the first time that N 3 -benzyl substituted uridine caused loss of righting reflex in mice by intracerebroventricular (i.c.v.) injection for the assessment of hypnotic activity ( Figure 3 ). This injection method 20 that bypasses peripheral effects, such as metabolism and blood-brain barrier, is able to evaluate CNS activity directly. The behavior of loss of righting reflex in rodents indicates the state of hypnotic action in a pharmacological experiment. In 1985, we demonstrated that N 3 -benzyluridine exerted the hypnotic action in mice. 21 Further systematic syntheses of nucleoside derivatives were then carried out using N 3 -benzyluridine as a lead compound. 22-34 N 3 -Substituted methyl, ethyl, propyl, butyl, allyl, benzyl, o-,m,p-xylyls, α-phenethyl, phenacyl, and their related derivatives were also synthesized by the method of Sasaki et al. 35 Although uridine is shown to promote natural sleep in rats, uridine does not have any hypnotic activity assessed by the loss of righting reflex in mice. N 3 -Alkyl and allyl substituted derivatives, N 3 -methyl, ethyl, propyl, butyl, and allyl, did not exert hypnotic activity in mice by i.c.v. injection, while certain derivatives of these compounds potentiated the effects induced by barbiturates and benzodiazepines. The synergistic effects were proportional to carbon numbers of the substitution group, especially allyl group (CH 2 =CH-CH 2 -). Interestingly, the structure of benzyl group contains the allyl moiety in the structure. N 3 -Benzyluridine exhibited hypnotic activity in mice by i.c.v. injection. Another functional groups of N 3 -benzyluridine such as halogenated benzyl, o,m,p-xylyls, α-phenyethyl groups were also effective in producing the hypnotic activity. Thus, we found that oxopyrimidine nucleoside derivatives exhibited the hypnotic activity. Subsequently, further study of the structure-activity relationship has been conducted to find more potent compounds. Namely, 1) introduction of a functional group to N 3 -position of uridine; 2) modification of sugar moiety of the N 1 -position (2-deoxyribose, arabinose, tetrahydrofuran, etc.; and 3) modification of nucleic base (thymine, 6-azauracil). N 3 -Phenacyl (C 6 H 5 -CO-CH 2 -) substituted uridine was successfully found to be the most potent hypnotic compound in this study ( Figure 3 ), though N 3 -phenyl acetyl (C 6 H 5 -CH 2 -CO-) derivative was not been able to be synthesized. The hypnotic activity of N 3 -phenacyluridine was 16-fold higher than that of N 3 -benzyluridine found previously. 26 Similarly, studies of structure-activity relationship of uracil and thymine derivatives indicated the requirement of sugar moiety at N 1 -posion of nucleic base moiety. In general, nucleoside has a glycosidic linkage between N 1 -position of oxopyrimidine ring and the ribose, allowing free rotation between both moieties. The fixation of free rotation of the glycosidic linkage by 6,3'-methanouridine is a good model for studying CNS depressant activity of N 3 -substituted oxopyrimidine nucleoside at the point of stereospecificity (anti and syn forms of N 3 -substituent base moiety). N 3 -Benzyl and/or phenacyl substituted uracil or thymine did not cause any hypnotic action in mice, recognizing the importance of the sugar moiety. It is noted that N 3 -phenacyluridine is extremely strong in hypnotic activity among N 3 -phenacyl substituted oxopyrimidine derivatives tested. The finding that stereospecificity of oxopyrimidine nucleoside derivatives is essential for inducing CNS depressant effects suggests an existence of binding sites for the compounds that are active.
In conclusion, substitution with functional groups at the N 3 -position of the oxopyrimidine base and at the hydroxy groups of the sugar moiety could be an important factor for producing CNS depressant effects of oxopyrimidine nucleoside derivatives.
Hypnotic Activities of Uridine Derivatives
N 3 -Benzyluridine and N 3 -phenacyluridine dose-dependently exhibited hypnotic activity in mice by i.c.v. injection. The hypnotic effect of N 3 -benzyluridine was three-fold higher than that of thiopental at the same dose. 21 For the detail pharmacological evaluation, synergism with other hypnotics, such as pentobarbital and diazepam, were also examined. N 3 -Phenacyluridine significantly prolonged the pentobarbital-induced sleep (by about six-fold) following i.c.v. injection, while combination of N 3 -phenacyluridine and diazepam remarkably resulted in 70-fold increase in diazepam-induced sleep. 26 N 3 -Phenacyluridine decreased spontaneous activity by 15% of the control level by i.c.v. injection in mice, even at a low dose of 0.5 µmol/mouse. 26 With respect to the spontaneous activity of oxopyrimidine nucleosides, Krooth et al. 36 reported that natural pyrimidines decreased spontaneous activity in mice. Motor incoordination experiment has been used for the evaluation of a drug as a potential tranquilizer. The results obtained from this line of experiments showed that N 3 -phenacyluridine induced motor incoordination. 26 Antianxiety effects of N 3 -phenacyluridine were also evaluated using shuttle box test and Swimming test in mice. 37 After i.c.v. injection of N 3 -phenacyluridine, the period for staying in the light side was significantly prolonged. N 3 -Phenacyluridine also shortened the swimming time of mice, indicating that this nucleoside derivative widely acted on the CNS depressant system.
Effects of N 3 -Benzyluridine on Natural Sleep
Natural sleep was classified into slow-wave sleep (SWS) and paradoxical sleep (PS), and distinguished from artificial sleep induced by hypnotics and/or tranquilizer. Furthermore, the natural sleep keeps the intervals and cycles of both SWS and PS. Uridine, one of the sleep-promoting substances, increased the frequency of the sleep without affecting both quality and quantity of the sleep determined by electroencepharogram. The noc- turnal i.c.v. infusion of uridine showed the onset of natural sleep in rats; 7 however, uridine did not induce any hypnotic action such as the loss of righting reflex.
Hypnotic activity of N 3 -benzyluridine on the natural sleep was also studied. Continuous nocturnal infusion of N 3 -benzyluridine into the third ventricle of unrestrained rats resulted in the slight sleep-promoting effect as shown in Figure 4 . 38 Throughout the experiment, sleep pattern of SWS and PS was not altered, indicating that experimental rats also had natural sleep. However, cumulative time of PS during the period of nocturnal infusion of N 3 -benzyluridine, but not SWS was 1.4 fold of the control. Since N 3 -benzyluridine produced the natural sleep promoting effect, study on the recovery after the termination of drug infusion was also conducted at the doses of 1 and 10 pmol. The results are expressed as total time, frequency, and duration of episodes in the control, test, and recovery period. Infusion of N 3 -benzyluridine, 1pmol, resulted in a significant increase in the total time and frequency of PS in the light period of the recovery. In contrast, infusion of N 3 -benzyluridine at 10 pmol, significantly enhanced SWS frequency in the same period, and tended to increase the total time of SWS. However, duration of episodes was not changed. These data slightly differed from those of uridine, because uridine did not enhance PS and SWS in the light period of recovery. Although the sleep-promoting effects of uridine were still evident during recovery period, the potentiation of sleep was limited in the dark period. Furthermore, 10 pmol of N 3 -benzyluridine failed to facilitate the sleep-promoting effect on the total time of PS in nocturnal infusion period.
It was also reported from our laboratory 21 that induction of hypnotic action required high doses of N 3 -benzyluridine in mice. In the study mentioned above, N 3 -benzyluridine exerted sleeppromoting effects at low doses (1 and 10 pmol). The results suggest that the mechanism of natural sleep of N 3 -benzyluridine may be different from that of artificially induced sleep such as the loss of righting reflex in mice. In addition, the sleep-promoting effect of N 3 -benzyluridine, an exogenous compound, may be different from that of uridine. Our observation in these experiments shows that N 3 -benzyluridine may play a role in sleep regulation as an intermediate between natural sleep and artificial sleeps.
Interaction of Uridine Derivatives with CNS Receptors
As mentioned above, the structure of base moiety of uridine is similar to that of barbiturates. It is well known that benzodiazepine binding site is coupled to γ-aminobutyric acid (GABA) binding site, chloride channel, picrotoxin binding site and barbiturate active site to form a GABA A receptor complex in the brain. 39, 40 Certain barbiturates affect benzodiazepine and GABA bindings. 39, 41 Furthermore, it is known that pentobarbital increased [ 3 H]diazepam binding to synaptic membranes in the presence of chloride ion. Therefore, we predicted that uridine derivatives also affect the GABA-benzodiazepine receptor-chloride channel complex because of the structural similarity to barbiturates. The interaction of N 3 -phenacyluridine with CNS depressants was also examined using barbiturate and benzodiazepine, since uridine and its related compounds are known to enhance drug-induced narcosis and motor incoordination. 22,24 N 3 -Phenacyluridine significantly prolonged the pentobarbitalinduced sleep (by about six-fold) following i.c.v. injection, while concomitant injection of N 3 -phenacyluridine and diazepam resulted in about 70-fold increase as described previously. 26 Therefore, it is important to study the effects of N 3 -substituted uridine on benzodiazepine receptor binding by using N 3 -phenacyluridine as a model compound. These results indicated that benzodiazepine receptor may be partly involved in the mechanism of action of N 3 -phenacyluridine.
Barbiturates are known to increase the benzodiazepine receptor binding in the presence of chloride ion. As shown in Figure  5 , pentobarbital increased the [ 3 H]flunitrazepam binding to synaptic membranes, while N 3 -phenacyluridine reversely decreased the binding, giving IC 50 of 129 µM. The results indicate that effect of N 3 -phenacyluridine on benzodiazepine receptor could be distinguished from that of barbiturates. 42 The Scatchard analysis revealed that the affinity of flunitrazepam for benzodiazepine binding site was affected by N 3 -phenacyluridine, while the apparent number of the binding sites remained unchanged (Figure 6 ). Asano and Spector 43 reported that inosine and hypoxanthine, but not uracil and cytosine, were identified as endogenous ligands for benzodiazepine binding site. We successfully found that these oxopyrimidine derivatives also interacted with the benzodiazepine site. The results suggest that N 3 -phenacyluridine may partly act on benzodiazepine site of the GABA A receptor as an agonist, though the affinity to the receptor is low.
Since N 3 -phenacyluridine interacted with benzodiazepine binding site, N 3 -phenacyluridine may affect GABA A receptor and chloride ionophore through the benzodiazepine binding site. Interaction of uridine with GABA binding sites in cerebellar membranes of rats was also reported by Guarneri et al. 44, 45 However, the ability of uridine to compete with GABA at its binding sites required much higher concentration of uridine (1 mM). We also showed that N 3 -benzyluridine interacted with GABA binding. 25 The Scatchard plot of GABA binding with 1 mM of N 3 -benzyluridine showed an increase in the dissociation constant without changes in the Bmax, indicating a competitive inhibition of the GABA binding by high concentration of N 3 -benzyluridine.
In summary, these results suggest that the pharmacological activity of oxopyrimidine nucleoside derivatives may be partially mediated through the benzodiazepine and GABA binding sites of the GABA A receptor.
Specific Binding Site of Uridine and its Derivatives
We have demonstrated that N 3 -phenacyluridine interacted with benzodiazepine binding site in bovine synaptic membrane. However, affinity of N 3 -phenacyluridine to the benzodiazepine binding site was low. 42 In addition, interaction of uridine with GABA binding site in cerebellar membranes of rats was also reported by Guarneri et al. 44, 45 and Yamamoto et al., 25 although the ability of uridine to compete with GABA at its binding sites needed much higher concentration of uridine at 1 mM. However, these studies failed to provide strong rationale for the hypnotic activity of N 3 -substituted uridine derivatives. These results raise the possibility that uridine derivatives may bind to a new type of receptor site for their CNS depressant activity. Therefore, [ 3 H]N 3 -phenacyluridine was synthesized from [ 3 H]uridine, and radioreceptor assay was performed for identifying novel binding site of N 3 -phenacyluridine.
Crude synaptic membranes from bovine thalami were prepared according to the method of Zukin et al. 46 [ 3 H]N 3 -Phenacyluridine binding assay was performed with Tris-HCl buffer (pH 7.4), containing synaptic membranes, dipyridamole (uptake inhibitor), and EDTA. The incubation conditions were set at 4°C for five minutes As shown in Figure 7 , [ 3 H]N 3 -phenacyluridine bound to synaptic membranes in a concentration-dependent manner. 47 Scatchard plot showed a single component of the binding site with the apparent K D of 0.73±0.05 nM and B max of 62±2 fmol/mg protein. The receptor distribution in the brain also should give an important information for the study of sleep mechanism. Therefore, specific [ 3 H]N 3 -phenacyluridine bindings in the rat brain were also measured. The data indicated that the binding was evident in the striatum, thalamus, cerebral cortex, and cerebellum. 48 Adenosine differs from oxopyrimidine nucleoside in that it has a purine base in the structure. The mechanism of CNS effects of adenosine, xanthine, and other purine was already studied more in term of receptor theory than that of oxopyrimidines. Because structure of purine consists of uracil moiety, therefore, effects of adenosine receptor ligands to uridine receptor binding were then examined. 47 The results showed that cyclopentyl-1,3-dipropylxanthine (A 1 antagonist) did not alter uridine binding, while 2-chloroadenosine (A 2 agonist) decreased 35% of the specific binding. However, the inhibition of binding required higher concentration of 2-chloroadenosine, indicating indirect interaction between adenosine binding ligands and uridine binding site. Therefore, we suggest that uridine binding site is located closely to adenosine binding site, and functionally acting together to produce CNS depressant activity including hypnotic action.
Pharmacological Effects and Receptor Binding of N 3 -(R)-(-)-and N 3 -(S)-(+)-α α-Hydroxy-β β-Phenethyluridine
In order to elucidate more of our "uridine receptor" theory, the metabolism and distribution of N 3 -benzyluridine and N 3 -benzylthimidine were conducted. The results obtained indicate that their metabolites do not contribute to the hypnotic activity of the parent compounds. 49, 50 However, metabolite of N 3 -phenacyluridine is different from that of N 3 -benzyluridine because of having a ketone moiety in the N 3 -substituent group. It is known that certain drugs that have ketone moiety are reduced to hydroxy group by reductase in the cytosol and produces active metabolites. It is thus expected that N 3 -phenacyluridine is also metabolized to the reduced form (alcohol). 51 Acetohexamide is widely used as an orally antidiabetic drug and possesses ketone group in the structure like N 3 -phenacyluridine. In humans, acetohexamide has been reported to be mainly biotransformed to (-)-hydroxyhexamide which is a pharmacologically active metabolite. 52 In addition, McMahon et al. 53 reported that (-)-hydroxyhexamide was 2.4 times as potent as acetohexamide on the pharmacological effect. N 3 -Phenacyluridine was metabolized to N 3 -α-hydroxy-β-phenethyluridine in mice as shown in Figure 8 . 51, 54 The N 3 -α-hydroxy-β-phenethyluridine can be subdivided into (R)-and (S)-isomers which derived from asymmetric carbon of phenacyl moiety. We successfully separated these isomers by HPLC. Pharmacological effects of N 3 -phenacyluridine and the isomers of the N 3 -α-hydroxy-β-phenethyluridines were evaluated by CNS depressant activities in mice by i.c.v. injection. N 3 -Phenacyluridine was mainly metabolized to N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine in mice as an active metabolite, while N 3 -(R)-(-)-α-hydroxy-β-phenethyluridine was not found as a metabolite.
The compound tested was injected by i.c.v. to mice, then sleeping time of the compound was measured as the time between the loss of righting reflex and the recovery in mice. N 3 -Phenacyluridine and N 3 -α-hydroxy-β-phenethyluridine (racemate mixture), 2.0 µmol/mouse, i.c.v., produced 487 and 279 min of sleep time, respectively, indicating that N 3 -α-hydroxy-β-phenethyluridine is an active metabolite (Table 1) . Moreover, it appeared that the hypnotic activity of N 3 -α-hydroxy-β-phenethyluridine showed stereospecificity. N 3 -(S)-(+)-α-Hydroxy-β-phenethyluridine induced 409 minutes of the sleeping time in mice, while N 3 -(R)-(-)-α-hydroxy-β-phenethyluridine only induced 27 min of the sleeping time. 54 We have further examined Table 1 . Ki value of N 3 -phenacyluridine was 0.65 nM, and these for α-hydroxy-β-phenethyluridine (racemic mixture), N 3 -(R)-(-)-and N 3 -(S)-(+)-α-hydroxy-β-phenethyluridines were 397.4, 1908, and 10.2 nM, respectively.
In conclusion, N 3 -phenacyluridine and the active metabolite, N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine, bound to uridine binding site. It is therefore thought that the hypnotic effects of oxopyrimidine nucleoside derivatives are mediated through their interaction with the uridine receptor. The data obtained further provide strong evidence to support that uridine is one of these sleep substances in mammals.
CONCLUSION
We synthesized derivatives of oxopyrimidine nucleosides, uridine, thymidine, 6-azauridine, 2'-deoxyuridine, and 2',3'-O-isopropylideneuridine, to study the structure-activity relationship for CNS depressant effects. [21] [22] [23] [24] [25] [26] From the results obtained, it appeared that hypnotic activity of the derivatives needed at least 2 key moieties in the structure. Namely, an aromatic group at N 3 position of oxopyrimidine ring and hydroxyl groups of the sugar moiety were essentially important for the hypnotic activity. In other words, these moieties fit the recognition points of the active site in the brain. As already mentioned above, uridine itself has CNS depressant property such as anticonvulsant effects and 257 Figure 9 -Postulated mechanism of hypnotic activity of oxopyrimidine nucleoside derivatives. we propose that phenomenon of sleep and wakefulness is a reversible physical action, endogenous substances such as uridine might be utilized in the de novo syntheses of this kind of nucleic acid. uridine receptor mainly mediates the hypnotic action of derivatives of oxopyrimidine nucleoside. Although the derivatives also interacted with GABA, benzodiazepine, 5-HT, and adenosine receptors, the affinities for these receptors were weak. REM Sleep: rapid eye movement sleep, NonREM Sleep: none rapid eye movement sleep GABA: γ-amonobutyric acid, 5-HT: 5-hydroxytryptamine Catabolism Anabolism Nucleic acid decrease in spontaneous activity of experimental animal. 19, 36 However, there was no evidence regarding the sleep/hypnotic effects of oxopyrimidine nucleosides until 1983. 11 It was noted that uridine is one of the sleep-promoting substances from sleepdeprived rat brainstems. Since the brainstem is known to generate REM sleep by cholinergic system, uridine may play an important role in the area. 55 The report encouraged us to study the relationship between uridine and CNS depressant effects including physical function of it. We then first demonstrated that a derivative of oxopyrimidine nucleoside, N 3 -benzyluridine, exhibited hypnotic activity in mice. 21 In addition, nocturnal infusion of N 3 -benzyluridine induced natural sleep in unrestrained rats and suggested that uridine derivative partly promote the natural sleep in rats. 38 Therefore, oxopyrimidine derivative may be useful for developing a new type of hypnotics which has the property between the endogenous and exogenous substances. The results further support the notion that uridine is a sleep factor (sleep-promoting substance) reported by Inoue et al. 7 More than 200 compounds have been synthesized in our laboratory, and N 3 -phenacyluridine exhibited the strongest hypnotic activity as tested in mice. 26 Low dose of N 3 -phenacyluridine exhibited decrease in spontaneous motor activity, motor incoordination, and antianxiety effects in mice, therefore, N 3 -phenacyluridine might have tranquilizer-like effects.
At the present, the mechanism of oxopyrimidine nucleosides induced CNS depressant is still unclear. We examined effects of oxopyrimidine nucleosdies on certain CNS receptors. However, the real action site of the oxopyrimidine nucleosides in the CNS is not attributed to the GABA, benzodiazepine, and adenosine receptors. 25, 42, 47 In addition, 5-HT system also involved in the regulation of the sleep-wake cycle. 56 Therefore, effects of oxopyrimidine nucleoside derivatives on 5-HT receptor bindings to synaptic membrane were examined using These results indicated that hypnotic mechanism of uridine derivative was not involved in the 5-HT system, suggesting the existence of another active site for uridine derivatives.
We found the specific [ 3 H]N 3 -phenacyluridine binding in synaptic membranes of mice, rats, and bovines, and the binding site was widely distributed in the striatum, thalamus, cerebral cortex, and cerebellum. 47, 48 From these results, [ 3 H]N 3 -phenacyluridine binding site was proposed as an "uridine receptor," which may play an important role in the CNS depressant effects of oxopyrimidine nucleosides. Recently, purine receptors were well established by many investigators, and mainly divided into two family of purine receptors (i.e., adenosine/P1 receptors and P2 receptor.) 57 However, there is only indirect evidence of P2Y receptor because of lack of the specific ligands for the receptor. Since the P2Y receptors have a affinity to uridine triphosphate, [57] [58] [59] contribution of oxopyrimidine nucleoside derivatives to the receptor was also speculated.
We revealed that N 3 -phenacyluridine was biotransformed to N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine in mice as an active metabolite. 54 The N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine exhibited hypnotic activity and synergistic effects with barbiturates by i.c.v. injection in mice. Displacement ability of specific [ 3 H]N 3 -phenacyluridine binding to synaptic membranes of the bovine thalamus by N 3 -(S)-(+)-α-hydroxy-β-phenethyluridine was higher than that of the (R)-(-)-isomer. Since these enantiomers have different pharmacological potency and binding affinity to the binding site, the results may account for the mechanism of action of oxopyrimidine nucleosides in the CNS depressant activity, especially the hypnotic activity.
As shown in Figure 9 , we propose that the phenomenon of sleep and wakefulness is a reversible physical action; endogenous substances such as uridine might be utilized in de novo syntheses of this kind of nucleic acid. In the studies conducted, we hypothesized that the uridine receptor mainly mediates the hypnotic action of derivatives of oxopyrimidine nucleoside. We initially examined the receptor binding assay using [ 3 H]uridine as a ligand. It was found that the uridine binding affinity to synaptic membranes of bovine thalami is lower than that of [ 3 H]N 3 -phenacyluridine (data are not shown). Since pharmacological and physical effects of uridine were not so strong, the low binding affinity of uridine to uridine receptor was explicable. If uridine possesses strong sleep response in mammals, the binding affinity of uridine must be higher and relatively specific, such as causing some disease like narcolepsy. Additional explanation is that the phenomenon of natural sleep is a delicate and physical condition; therefore the receptor response of uridine is mild. We have successfully found the uridine receptor using [ 3 H]N 3 -phenacyluridine as a specific ligand. Other CNS receptors mentioned above may also interact with this receptor with complicated factors such as allosteric effects, second messengers, competition at the binding sites and so on. However, these interactions of the CNS receptors in vitro require much higher concentration of the compound. Therefore, uridine receptor is believed to preliminary mediates the hypnotic activity of oxopyrimidine nucleoside.
In the present communication, we propose a new concept of uridine receptor for hypnotic action. Future study of uridine receptor in the field of molecular biology will contribute to elucidate the physical function of oxopyrimidine nucleosides in the CNS.
